PEBC Report - Programa de Epigenética y BiologÃa del Cáncer
PEBC Report - Programa de Epigenética y BiologÃa del Cáncer
PEBC Report - Programa de Epigenética y BiologÃa del Cáncer
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Dr Dave Monk<br />
Genomic Imprinting and Cancer Group<br />
David Monk (London, United Kingdom, 1975) graduated<br />
from Anglia Ruskin University, Cambridge with a B.Sc (Hons)<br />
in Biomedical science before un<strong>de</strong>rtaking an M.Sc in<br />
Human Reproductive Biology at Imperial College London.<br />
In 2001 he wrote his PhD thesis on the genetic aetiology of<br />
Silver-Russell syndrome, a project mentored by Professors<br />
Michael Preece and Gudrun Moore at Queen Charlotte’s<br />
and Chelsea Hospital (QCCH), Imperial College London.<br />
From 2001-2004 he was a Postdoctoral Researcher fun<strong>de</strong>d<br />
by the MRC to screen for novel imprinted genes using<br />
DNA methylation based technologies. This position was a<br />
multi-site collaborative project, which saw him spend time in<br />
the laboratories of Professor Moore, now at the Institute of<br />
Reproductive and Developmental Biology (IRDB) Imperial<br />
College London, Dr Gavin Kelsey at The Babraham Institute<br />
Cambridge, and with Professor Jo Peters at MRC Harwell.<br />
From 2005-2007, Dr Monk was a March of Dimes fun<strong>de</strong>d<br />
Postdoctoral Research Fellow at the IRDB, un<strong>de</strong>rtaking<br />
research into the epigenetic regulation of placental imprinting<br />
in the human, and the involvement of imprinted gene<br />
expression in human fetal growth. During this time he was<br />
awar<strong>de</strong>d an EMBO short-term fellowship to spend time in<br />
the laboratory of Dr Robert Feil in CNRS, Montpellier France.<br />
In 2007, he was appointed as Lecturer in Molecular<br />
Epigenetics and Paediatric Oncology at the Institute of Child<br />
Health, University College London. Since the summer of<br />
2008, Dr Monk is the Principal Investigator of the Genomic<br />
Imprinting and Cancer group within the Cancer Epigenetics<br />
and Biology Program of the Catalan Institute of Oncology<br />
(ICO) in Barcelona. His current research interests inclu<strong>de</strong>:<br />
Aberrant epigenetic modifications and imprinting in MLL<br />
translocation leukaemias; Altered DNA methylation and<br />
imprinting profiles in cancers; and <strong>de</strong>fining epigenetic signatures<br />
for loss-of-imprinting that occur in cancer and imprinting<br />
disor<strong>de</strong>rs.<br />
PhD Stu<strong>de</strong>nts: Amy Guilaumet Adkins,<br />
Alejandro Martin Trujillo<br />
Visiting Stu<strong>de</strong>nt: Alberto Garcia Lopez<br />
Epigenetics is the term used in biology to refer to chromatin<br />
structure and DNA modifications that are stable over rounds<br />
of cell division but do not involve changes in the DNA<br />
sequence. Epigenetics play a pivotal role in cellular differentiation,<br />
allowing cells to stably maintain different characteristics<br />
<strong>de</strong>spite containing the same genomic DNA. Epigenetic<br />
processes are also involved in gene silencing, X chromosome<br />
inactivation, reprogramming and are thought to be<br />
one of the major limitations to cloning. One of the main<br />
interests of this group is Genomic Imprinting. Imprinted<br />
genes are expressed from only one parental allele, the other<br />
is silenced by epigenetic modifications, classically involving<br />
43